US FDA approves the next-generation, AI-powered platform for Aquablation therapy-PROCEPT BioRobotics’ HYDROS Robotic System

PROCEPT BioRobotics Corporation has received FDA 510(k) clearance for its next-generation HYDROS Robotic System. This advanced platform, designed for Aquablation therapy, integrates insights from over 50,000 procedures and features FirstAssist AI treatment planning, advanced image guidance, robotic resection, and a streamlined workflow.

Key features include:

- AI-Powered Treatment Planning: FirstAssist AI uses real-time ultrasound to suggest optimal treatment plans.

- Advanced Image Guidance: Combines next-gen ultrasound, digital cystoscopy, and dual high-definition touchscreens for enhanced visualization.

- Robotic Resection: Utilizes a heat-free waterjet for precise, controlled tissue removal while protecting critical anatomy.

- Streamlined Workflow: Features an integrated tower for efficient setup, an adjustable touchscreen for better ergonomics, and intuitive software for a smoother process.

The HYDROS System is the only AI-powered platform for Aquablation therapy, offering personalized, precise treatment with proven long-term symptom relief.